|
05/27/2004 - MOCH NAMED BIOTECHNOLOGY COUNCIL OF NEW JERSEY CHAIRMAN
TRENTON---May 27, 2004 - The Biotechnology Council of New Jersey (BCNJ) has announced that Kenneth I. Moch, President and CEO of Alteon Inc. in Parsippany, NJ, has been elected Chairman of the Council. Mr. Moch succeeds Arthur Higgins, who resigned from his position as Chairman of the Council after accepting a position as Chairman and CEO of Bayer Healthcare, a $10 billion global diversified healthcare company headquartered in Leverkussen, Germany.
Mr. Higgins and Mr. Moch have worked together as officers of the BCNJ since January 2003. Mr. Moch most recently served as the Council's Vice Chairman, and has been a member of BCNJ's board of directors since January 1999.
Commenting on his resignation, Mr. Higgins said: "It has been an honor to serve as chairman of the Biotechnology Council of New Jersey, it is with great regret that I tender my resignation. Given New Jersey's longstanding recognition as a leader in the life science industry, I have thoroughly enjoyed and been enriched by my experiences as chairman."
Mr. Moch said he was proud to succeed Mr. Higgins as chairman. "New Jersey's biotechnology industry has not only helped to stimulate economic growth within our State, it has also brought important products to the marketplace for patients with serious unmet medical needs. Since 1994, the BCNJ has served as the industry voice for this State's biotechnology community and I am honored to serve as Chairman of this dedicated and successful organization. I look forward to working with my fellow board members to continue to build upon New Jersey's solid foundation and capture the enormous growth opportunity that biotechnology represents to the State of New Jersey."
BCNJ President Debbie Hart commented on Mr. Higgin's contributions to the Council and Mr. Moch's future leadership. "It was under Arthur's leadership that BCNJ participated in the Porter Study, the Governor's Commission on Jobs, Growth and Economic Development and embarked on an initiative to bring more federal monies into the state. We have been fortunate to have such a leader during these exciting times. We are also pleased to have Kenneth Moch assume the leadership of BCNJ, as Ken's broad experience as a biotech entrepreneur and proactive, high energy leadership style will benefit New Jersey's biotech industry with a hand's on approach."
Mr. Moch joined Alteon in 1995 as Senior Vice President, Finance & Business Development and Chief Financial Officer, became President and Chief Executive Officer in 1998, and was named to the additional title of Chairman in 2001. Mr. Moch has acquired substantial experience in managing advanced biomedical technologies, as both
an operating executive and a strategist. From 1990 to 1995, he served as President and Chief Executive Officer of Biocyte Corporation, a cellular therapy company that pioneered the use of cord blood stem cells in transplantation therapy. He was a cofounder and Vice President of The Liposome Company, Inc. in Princeton, New Jersey, from 1982 to 1988, and served as a consultant with McKinsey & Company Inc. and Channing/Weinberg (The Wilkerson Group). Mr. Moch holds a degree in biochemistry from Princeton University and an MBA from Stanford University.
Founded in 1994, the sole mission of the Biotechnology Council of New Jersey is to promote a business and public policy environment in the state of New Jersey and beyond that enhances the growth and prosperity of New Jerseys biotechnology companies. BCNJ currently has 150 member companies.
Back
|